Celularity receives Nasdaq notice for late filing of Q1 2024 Form 10-Q and 2023 Form 10-K, with deadline to submit compliance plan by June 17.
Celularity, a regenerative medicine company, has received a notice from Nasdaq for late filing of its Form 10-Q for Q1 2024 and delinquency in filing its 2023 Form 10-K. The company has until June 17 to submit a plan to regain compliance, with a deadline of October 14 to implement it. Celularity is working on filing the required reports and evaluating options to regain compliance within the given timeframe.
May 24, 2024
3 Articles